A Review of Trastuzumab-Based Therapy in Patients with HER2-positive Metastatic Breast Cancer

被引：0

作者：

Church, David N. ^{[1
]}

Price, Chris G. A. ^{[2
]}

机构：

[1] Univ Oxford, John Racliffe Hosp, Weatherall Inst Mol Med, Headley Way, Oxford OX3 9DS, England

[2] Bristol Haematol & Oncol Ctr, Bristol BS1 8ED, Avon, England

来源：

CLINICAL MEDICINE INSIGHTS-THERAPEUTICS | 2009年 / 1卷

关键词：

breast cancer; trastuzumab; metastatic; ERBB2; HER2;

D O I：

暂无

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The ERBB2 or HER2 receptor is overexpressed in 25% of breast cancers and is associated with poor prognosis. Trastuzumab, a monoclonal antibody targeting HER2 has been demonstrated to improve survival when combined with chemotherapy for the treatment of HER2 overexpressing metastatic breast cancer (MBC). Further studies have endeavoured to clarify the optimum chemotherapy regimen in combination with trastuzumab for MBC and its use together with novel biological agents. This review summarises these data together with preclinical studies exploring the mechanism of trastuzumab action and causes of drug resistance. The frequent incidence of brain metastases in patients on trastuzumab is highlighted, and data on the continuation of trastuzumab following CNS and non-CNS progression reviewed.

引用

页码：557 / 570

页数：14

共 149 条

[1] Safety and activity of trastuzumab-containing therapies for the treatment of metastatic breast cancer:: our long-term clinical experience (GOIM study) [J].

Adamo, V. ;

Franchina, T. ;

Adamo, B. ;

Ferraro, G. ;

Rossello, R. ;

Sacca, M. Maugeri ;

Scibilia, C. ;

Valerio, M. R. ;

Russo, A. .

ANNALS OF ONCOLOGY, 2007, 18 :11-15

[2] Serum HER-2/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer [J].

Ali, Suhail M. ;

Carney, Walter P. ;

Esteva, Francisco J. ;

Fornier, Monica ;

Harris, Lyndsay ;

Koestler, Wolfgang. J. ;

Lotz, Jean-Pierre ;

Luftner, Diana ;

Pichon, Marie-France ;

Lipton, Allan .

CANCER, 2008, 113 (06) :1294-1301

[3] ASSOCIATION OF C-ERBB-2 EXPRESSION AND S-PHASE FRACTION IN THE PROGNOSIS OF NODE POSITIVE BREAST-CANCER [J].

ANBAZHAGAN, R ;

GELBER, RD ;

BETTELHEIM, R ;

GOLDHIRSCH, A ;

GUSTERSON, BA .

ANNALS OF ONCOLOGY, 1991, 2 (01) :47-53

[4] Feasibility and cardiac safety of pegylated liposomal doxorubicin plus trastuzumab in heavily pretreated patients with recurrent HER2-Overexpressing metastatic breast cancer [J].

Andreopoulou, Eleni ;

Gaiotti, Darci ;

Kim, Eugene ;

Volm, Matthew ;

Oratz, Ruth ;

Freedberg, Robin ;

Downey, Andrea ;

Vogel, Charles L. ;

Chia, Stephen ;

Muggia, Franco .

CLINICAL BREAST CANCER, 2007, 7 (09) :690-696

[5] neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer [J].

Andrulis, IL ;

Bull, SB ;

Blackstein, ME ;

Sutherland, D ;

Mak, C ;

Sidlofsky, S ;

Pritzker, KPH ;

Hartwick, RW ;

Hanna, W ;

Lickley, L ;

Wilkinson, R ;

Qizilbash, A ;

Ambus, U ;

Lipa, M ;

Weizel, H ;

Katz, A ;

Baida, M ;

Mariz, S ;

Stoik, G ;

Dacamara, P ;

Strongitharm, D ;

Geddie, W ;

McCready, D .

JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (04) :1340-1349

[6] A Phase I-II Study of Combined Blockade of the ErbB Receptor Network with Trastuzumab and Gefitinib in Patients with HER2 (ErbB2)-Overexpressing Metastatic Breast Cancer [J].

Arteaga, Carlos L. ;

O'Neill, Anne ;

Moulder, Stacy L. ;

Pins, Michael ;

Sparano, Joseph A. ;

Sledge, George W. ;

Davidson, Nancy E. .

CLINICAL CANCER RESEARCH, 2008, 14 (19) :6277-6283

[7] Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the metropolitan Detroit cancer surveillance system [J].

Barnholtz-Sloan, JS ;

Sloan, AE ;

Davis, FG ;

Vigneau, FD ;

Lai, P ;

Sawaya, RE .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) :2865-2872

[8] Trastuzumab and gemcitabine as salvage therapy in heavily pre-treated patients with metastatic breast cancer [J].

Bartsch, Rupert ;

Wenzel, Catharina ;

Gampenrieder, Simon P. ;

Pluschnig, Ursula ;

Altorjai, Gabriela ;

Rudas, Margaretha ;

Mader, Robert M. ;

Dubsky, Peter ;

Rottenfusser, Andrea ;

Gnant, Michael ;

Zielinski, Christoph C. ;

Steger, Guenther G. .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 62 (05) :903-910

[9] Results from an observational trial with oral vinorelbine and trastuzumab in advanced breast cancer [J].

Bartsch, Rupert ;

Wenzel, Catharina ;

Altorjai, Gabriela ;

Pluschnig, Ursula ;

Bachleitner-Hoffmann, Thomas ;

Locker, Gottfried J. ;

Rudas, Margaretha ;

Mader, Robert ;

Zielinski, Christoph C. ;

Steger, Guenther G. .

BREAST CANCER RESEARCH AND TREATMENT, 2007, 102 (03) :375-381

[10] Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule [J].

Baselga, J ;

Carbonell, X ;

Castañeda-Soto, NJ ;

Clemens, M ;

Green, M ;

Harvey, V ;

Morales, S ;

Barton, C ;

Ghahramani, P .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (10) :2162-2171

← 1 2 3 4 5 6 7 8 9 10 →